|Day's Range||2,546.50 - 2,612.20|
|52 Week Range||2,525.25 - 3,689.00|
|PE Ratio (TTM)||22.04|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: Asia Pacific Value Yahoo FinanceClick here to see latest analysis Capitalcube gives Dr. Reddy’s Laboratories Ltd. a score of 39. Our analysis is based on comparing Dr. Reddy’s Laboratories Ltd. with the following peers – Cipla Limited, Wockhardt Limited, Novartis India Limited, Lupin Limited, Glenmark Pharmaceuticals Limited and Cadila Healthcare Limited (500087-IN, 532300-IN, 500672-IN, 500257-IN, 532296-IN and 532321-IN). Investment ... Read more (Read more...)
Dr. Reddy’s Laboratories Ltd. announced today that it has received approval from the U.S. Food and Drug Administration to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil® , for intravenous use, in the United States market.
Categories: Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Dr. Reddy’s Laboratories Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day ... Read more (Read more...)